← Back
Scribe Therapeutics
SCTX · listed on Nasdaq · worth $500.02 million
$15.54
+0.78% on Nov 2
Nine insider buys in the last year, $71.34 million in all. None in the last two weeks.
Green dot = an insider boughtA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
892.6K shares
6% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, six insiders bought Scribe Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Behzad Aghazadeh
Bought $35M on Jul 24 — 2,333,333 shares at $15.00, held through a trust or family, 77% of what they now own.
No earlier purchases to measure
Director
Carl L. Gordon
Bought $15M on Jul 27 — 1,000,000 shares at $15.00, held through a trust or family, 74% of what they now own.
No earlier purchases to measure
Director
Orbimed Advisors LLC
Bought $15M on Jul 27 — 1,000,000 shares at $15.00, held through a trust or family, 74% of what they now own.
1 of 2 earlier purchases did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Scribe Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.RA Capital Management9.6%Aug 3
Filed by someone who owns 5% or more and may try to influence how the company is run.Avoro Capital Advisors LLC13.8%Jul 30
Filed by someone who owns 5% or more and may try to influence how the company is run.ELI LILLY & Co7.3%Jul 30
Filed by someone who owns 5% or more and may try to influence how the company is run.Orbimed Advisors LLC7.2%Jul 29
All reports
Every insider trade and SEC report we hold for Scribe Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Jul 29BoughtAH Bio Fund IIJul 29 · Traded Jul 27 · 10% owner+14%via a trust or family333,333 @ $15.00$5M
Jul 29BoughtCarl L. GordonJul 29 · Traded Jul 27 · Director+74%via a trust or family1,000,000 @ $15.00$15M
Jul 29BoughtOrbimed Advisors LLCJul 29 · Traded Jul 27 · Director+74%via a trust or family1,000,000 @ $15.00$15M
Jul 28BoughtBehzad AghazadehJul 28 · Traded Jul 24 · 10% owner+1.6%via a trust or family50,000 @ $22.31$1.12M
4 more with Pro →Analysts, earnings and news
Analysts' price target
$56.00 average
3 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 1 quarters above
Q2 '26−$2.62 a share+$1.10